Yi Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yi Wu has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Chunhai Fan
Shanghai Jiao Tong University
2 shared publications - Ping Song
School of Biomedical Engineering Zhangjiang Institute for Advanced Study and National Center For Translational Medicine Shanghai Jiao Tong University Shanghai China
2 shared publications - Xiaolei Zuo
Shanghai Jiao Tong University
2 shared publications - Xuehao Xiu
International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, National Center for Translational Medicine, Shanghai 200030, China
2 shared publications - Zhi Weng
International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, National Center for Translational Medicine, Shanghai 200030, China
2 shared publications David Yu Zhang
Biostate AI, Inc., Houston, TX, USA
1 shared publication
Latest Publications
- Open Access
- 27 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (13) , eaec9175
Machine learning–directed massively parallel programmable nucleic acid amplification
Dynamic regulation of amplification efficiency is pivotal yet challenging in molecular diagnostics and DNA data storage. Here, we develop a thermodynamics-based approach to achieve continuous and precise modulation of nucleic acid amplification efficiency. By decoupling sequence specificity from hybridization energy regulation via a primer-tag compensation strategy, we demonstrate programmed amplification with high resolution (33 versus 81%). Leveraging 2483 experimental data, we constructed a machine learning model that improved prediction accuracy from R 2 = 0.62 to = 0.86. In DNA data storage, this amplification strategy increases the density for information preview by nearly one order of magnitude and robust file steganography via differential amplification. In clinical validation, our method outperformed uniform amplification in cervical cancer RNA variant analysis, detecting rare RNA fusions and improving detection sensitivity by 100-fold under 10 4 simulated sequencing depth. This programmable technique is anticipated to extend to single-cell sequencing and spatial transcriptomics, offering a powerful tool for molecular diagnostics and synthetic biology.
- 27 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (13) , eaec9175
Open AccessMachine learning–directed massively parallel programmable nucleic acid amplification
Dynamic regulation of amplification efficiency is pivotal yet challenging in molecular diagnostics and DNA data storage. Here, we develop a thermodynamics-based approach to achieve continuous and precise modulation of nucleic acid amplification efficiency. By decoupling sequence specificity from hybridization energy regulation via a primer-tag compensation strategy, we demonstrate programmed amplification with high resolution (33 versus 81%). Leveraging 2483 experimental data, we constructed a machine learning model that improved prediction accuracy from R 2 = 0.62 to = 0.86. In DNA data storage, this amplification strategy increases the density for information preview by nearly one order of magnitude and robust file steganography via differential amplification. In clinical validation, our method outperformed uniform amplification in cervical cancer RNA variant analysis, detecting rare RNA fusions and improving detection sensitivity by 100-fold under 10 4 simulated sequencing depth. This programmable technique is anticipated to extend to single-cell sequencing and spatial transcriptomics, offering a powerful tool for molecular diagnostics and synthetic biology.
- 2 January 2026
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 10 (9) , 1855-1870
Anchored random reverse primer sequencing for quantitative detection of novel gene fusions
Identifying novel gene fusions is critical for cancer diagnosis and drug development. While a few advanced methods have shown the capability to detect gene fusions involving unknown partners, comprehensive detection of gene fusions, especially of those with low copy numbers, remains a challenge. Indeed, most current panel-based sequencing methods fall short in reliability and cost efficiency. Here we present a method for detecting potentially novel gene fusions using anchored random reverse primers (ARRP) during PCR-based library construction, allowing the simultaneous capture of mutations and RNA splicing variants. Furthermore, the combination with blocker displacement amplification technology enables a median of 22-fold allele enrichment for gene fusions, achieving a limit of detection ~10-fold lower than that of current technologies and resulting in an 8-fold cost reduction. Using ARRP-seq, we identify numerous novel fusions in 98 clinical tissue samples, showcasing its diagnostic potential in prostate cancer and capacity for personalized diagnostics in cervical cancer.
- 2 January 2026
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 10 (9) , 1855-1870
Anchored random reverse primer sequencing for quantitative detection of novel gene fusions
Identifying novel gene fusions is critical for cancer diagnosis and drug development. While a few advanced methods have shown the capability to detect gene fusions involving unknown partners, comprehensive detection of gene fusions, especially of those with low copy numbers, remains a challenge. Indeed, most current panel-based sequencing methods fall short in reliability and cost efficiency. Here we present a method for detecting potentially novel gene fusions using anchored random reverse primers (ARRP) during PCR-based library construction, allowing the simultaneous capture of mutations and RNA splicing variants. Furthermore, the combination with blocker displacement amplification technology enables a median of 22-fold allele enrichment for gene fusions, achieving a limit of detection ~10-fold lower than that of current technologies and resulting in an 8-fold cost reduction. Using ARRP-seq, we identify numerous novel fusions in 98 clinical tissue samples, showcasing its diagnostic potential in prostate cancer and capacity for personalized diagnostics in cervical cancer.